Info: Read More
  • 中药标准品生产商,产品定制服务
  • 白术内酯II; 苍术内酯II

    Atractylenolide II

    白术内酯II; 苍术内酯II
    产品编号 CFN99945
    CAS编号 73069-14-4
    分子式 = 分子量 C15H20O2 = 232.32
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Sesquiterpenoids
    植物来源 The rhizomes of Atractylodes macrocephala Koidz.
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    白术内酯II; 苍术内酯II CFN99945 73069-14-4 10mg QQ客服:215959384
    白术内酯II; 苍术内酯II CFN99945 73069-14-4 20mg QQ客服:215959384
    白术内酯II; 苍术内酯II CFN99945 73069-14-4 50mg QQ客服:215959384
    白术内酯II; 苍术内酯II CFN99945 73069-14-4 100mg QQ客服:215959384
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • Melbourne University (Australia)
  • University of Otago (New Zealand)
  • University of Illinois (USA)
  • Istanbul University (Turkey)
  • University of Helsinki (Finland)
  • Lund University (Sweden)
  • Amity University (India)
  • Stanford University (USA)
  • Heinrich-Heine-University Düsseldorf (Germany)
  • Indian Institute of Science (India)
  • Institute of Bioorganic Chemistry Polish Academy of Sciences (Poland)
  • National Cancer Institute (USA)
  • Centralised Purchases Unit (CPU), B.I.T.S (India)
  • University of Padjajaran (Indonesia)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Molecules.2023, 28(9):3685.
  • Bioengineering2023, 10(10), 1113.
  • J Chromatogr B Analyt Technol Biomed Life Sci. 2017, 1064:115-123
  • J Ethnopharmacol.2020, 249:112396
  • Eur Rev Med Pharmacol Sci.2020, 24(9):5127-5139.
  • Int J Mol Sci.2019, 21(1):E265
  • bioRxiv2021, 462065.
  • Semyung University2017, 149407
  • Molecules.2022, 27(4):1412.
  • Planta Medica International2022, 9(01):e108-e115.
  • Biomed Pharmacother.2022, 145:112474.
  • J Pharm Biomed Anal.2019, 164:119-127
  • J Chromatogr Sci.2015, 53(5):824-9
  • Applied Biological Chemistry2023, 66(58):112.
  • Int J Mol Sci.2018, 19(9):E2825
  • Chem Biol Interact.2022, 368:110248.
  • Evid Based Complement Alternat Med.2022, 2022:3483511
  • Adaptive Medicine 2020, 12(1): 4-10
  • Faculty of Chem. & Nat. Resource Eng.2014, 62
  • Front Pharmacol.2021, 12:615157.
  • Heinrich Heine University Dusseldorf2021, 62203.
  • The Japan Society for Analy. Chem.2017, 66(8):613-617
  • J Ethnopharmacol.2016, 194:219-227
  • ...
  • 生物活性
    Description: Atractylenolide II has antiinflammatory activity, it can inhibit platelets activities and thrombus formation. Atractylenolide II has cytotoxic/apoptotic effects may via p38 activation ,ERK and Akt inactivation, p53 dependent, it also has antimelanoma effect by inhibiting STAT3 signalling.
    Targets: STAT | Src | CDK | Akt | ERK | Bcl-2/Bax | p38MAPK | Caspase | p53 | p21
    In vitro:
    J. Am. Coll. Cardiol., 2015, 66(16):C44-C44.
    GW26-e1245 Atractylenolide II and Atractylenolide III Inhibit Platelets Activities and Thrombus Formation[Reference: WebLink]
    Atractylenolide II and Atractylenolide III Inhibit Platelets Activities and Thrombus Formation.
    Biomed Chromatogr. 2007 Mar;21(3):299-303.
    Determination of atractylenolide II in rat plasma by reversed-phase high-performance liquid chromatography.[Pubmed: 17236249]

    METHODS AND RESULTS:
    A method for quantitative determination of Atractylenolide II in rat plasma using reversed-phase high-performance liquid chromatography (RP-HPLC) coupled with UV spectrometry was established. From a variety of compounds and solvents tested, Atractylenolide III was selected as the internal standard (IS) and ethyl acetate was found to be the best solvent for extracting Atractylenolide II from plasma samples. RP-HPLC analysis of the extracts was performed on an analytical column (DIKMA ODS, 150 x 4.6 mm; i.d., 5 microm) equipped with a security guard pre-column system. There was good linearity over the range 0.05-5.0 microg/mL (r > 0.99). The recoveries were more than 90.0% in plasma, and the intra- and inter-day coefficients of variation were less than 10.0% in all cases. The limit of detection (LOD) was 0.025 microg/mL and the lower limit of quantification (LLOQ) was 0.05 microg/mL.
    CONCLUSIONS:
    The RP-HPLC method was applied to quantitate Atractylenolide II in rat plasma within 24 h in a pharmacokinetics study where experimental rats received a single dose of Atractylenolide II (60 mg/kg).
    Phytotherapy Research, 2007, 21(4):347-353.
    Antiinflammatory Principles of Atractylodes Rhizomes.[Reference: WebLink]
    The crude drug"jutsu"prepared from Atractylodes rhizomes has been used for antiinflammatory purposes in Oriental medicine.
    METHODS AND RESULTS:
    In fact, a preparation from A. japonica was found to show significant inhibition of the increased vascular permeability induced by acetic acid. Fractionation of the extract, monitoring by bioassay, resulted in the isolation of two active principles, (+)-eudesma-4 (14), 7 (11)-dien-8-one (VI) and atractylenolide I (VII).
    CONCLUSIONS:
    The structurally related principles Atractylenolide II and III (VIII and IX) also had the tendency to show antiinflammatory activity.
    Planta Med . 2017 Jul;83(11):901-911.
    Correlating In Vitro Target-Oriented Screening and Docking: Inhibition of Matrix Metalloproteinases Activities by Flavonoids[Pubmed: 28288492]
    Abstract Metalloproteases are a family of zinc-containing endopeptidases involved in a variety of pathological disorders. The use of flavonoid derivatives as potential metalloprotease inhibitors has recently increased.Particular plants growing in Sicily are an excellent yielder of the flavonoids luteolin, apigenin, and their respective glycoside derivatives (7-O-rutinoside, 7-O-glucoside, and 7-O-glucuronide).The inhibitory activity of luteolin, apigenin, and their respective glycoside derivatives on the metalloproteases MMP-1, MMP-3, MMP-13, MMP-8, and MMP-9 was assessed and rationalized correlating in vitro target-oriented screening and in silico docking.The flavones apigenin, luteolin, and their respective glucosides have good ability to interact with metalloproteases and can also be lead compounds for further development. Glycones are more active on MMP-1, -3, -8, and -13 than MMP-9. Collagenases MMP-1, MMP-8, and MMP-13 are inhibited by compounds having rutinoside glycones. Apigenin and luteolin are inactive on MMP-1, -3, and -8, which can be interpreted as a better selectivity for both -9 and -13 peptidases. The more active compounds are apigenin-7-O-rutinoside on MMP-1 and luteolin-7-O-rutinoside on MMP-3. The lowest IC50 values were also found for apigenin-7-O-glucuronide, apigenin-7-O-rutinoside, and luteolin-7-O-glucuronide. The glycoside moiety might allow for a better anchoring to the active site of MMP-1, -3, -8, -9, and -13. Overall, the in silico data are substantially in agreement with the in vitro ones (fluorimetric assay). Georg Thieme Verlag KG Stuttgart · New York.
    Biomed Pharmacother . 2018 Nov;107:1505-1513.
    Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN[Pubmed: 30257368]
    Abstract Background: Scutellarin is a naturally flavone glycoside that has been shown to exhibit anti-proliferative and anti-apoptotic activities among various human malignancies. However, the anti-cancer effect of Scutellarin in Renal cell carcinoma (RCC) and the underlying mechanism remains unclear. Methods and materials: RCC cell lines ACHN and 786-O were treated with different concentrations (0-210 μM) of Scutellarin in vitro. Cell viability and proliferation were investigated by MTT and colony formation assays. Cell invasion and migration were detected by Transwell assays. Cell apoptosis and cell cycle distribution was measured by flow cytometry. Western blot was used to investigate the expression levels of crucial proteins. Xenograft tumor model was established to evaluate tumor growth in vivo. Results: Scutellarin significantly inhibited RCC cell proliferation in a dose- and time- dependent manner. Treatment of RCC cells with Scutellarin (30, 60, and 90 μM) markedly induced apoptosis and cell cycle arrested at G0/G1 phase in a concentration-dependent characteristic. Cell invasion and migration capacities of RCC cells were also dose-dependently suppressed by Scutellarin treatment. Western blot assays revealed that the crucial proteins including cyclin D1, CDK2, Bcl2, MMP-2, and MMP-9 were significantly reduced while Bax, cleaved caspase 3 and p21 were increased by Scutellarin in RCC cells. In vivo assay indicated that Scutellarin possessed anti-cancer effect on xenograft without triggering toxic effect. Mechanically, Scutellarin dramatically increased the protein level of phosphatase and tensin homologue (PTEN) and inhibited the activity of P13K/AKT/mTOR signaling. Ectopic expression of PTEN enhanced the inhibitory effect of Scutellarin on RCC proliferation while knockdown of PTEN abrogated it through regulating its downstream P13K/AKT/mTOR signaling pathway. Conclusion: Scutellarin inhibited RCC cell proliferation and invasion partially by enhancing the expression of PTEN through inhibition of P13K/AKT/mTOR pathway, suggesting that Scutellarin might serve as a potential therapeutic agent in RCC treatment. Keywords: P13K/AKT/mTOR; PTEN; Proliferation; Renal cancer; Scutellarin.
    In vivo:
    Exp Dermatol. 2014 Nov;23(11):855-7.
    Inhibition of STAT3 signalling contributes to the antimelanoma action of atractylenolide II.[Pubmed: 25073716]
    Our previous studies showed that atractylenolide II (AT-II) has antimelanoma effects in B16 melanoma cells.
    METHODS AND RESULTS:
    In this study, we investigated the involvement of STAT3 signalling in the antimelanoma action of AT-II. Daily administration of AT-II (12.5, 25 mg/kg, i.g.) for 14 days significantly inhibited tumor growth in a B16 xenograft mouse model and inhibited the activation/phosphorylation of STAT3 and Src in the xenografts. In B16 and A375 cells, AT-II (20, 40 μm) treatment for 48 h dose-dependently reduced protein expression levels of phospho-STAT3, phospho-Src, as well as STAT3-regulated Mcl-1 and Bcl-xL. Overexpression of a constitutively active variant of STAT3, STAT3C in A375 cells diminished the antiproliferative and apoptotic effects of AT-II. These data suggest that inhibition of STAT3 signalling contributes to the antimelanoma action of AT-II.
    CONCLUSIONS:
    Our findings shed new light on the mechanism of action underlying the antimelanoma effects of AT-II and provide further pharmacological basis for developing AT-II as a novel melanoma chemopreventive/chemotherapeutic agent.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 4.3044 mL 21.522 mL 43.0441 mL 86.0882 mL 107.6102 mL
    5 mM 0.8609 mL 4.3044 mL 8.6088 mL 17.2176 mL 21.522 mL
    10 mM 0.4304 mL 2.1522 mL 4.3044 mL 8.6088 mL 10.761 mL
    50 mM 0.0861 mL 0.4304 mL 0.8609 mL 1.7218 mL 2.1522 mL
    100 mM 0.043 mL 0.2152 mL 0.4304 mL 0.8609 mL 1.0761 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    Chlorantholide C; Chlorantholide C CFN97970 1372558-35-4 C15H18O3 = 246.3 5mg QQ客服:2056216494
    Chlorantholide D; Chlorantholide D CFN97956 1253106-58-9 C15H18O4 = 262.3 5mg QQ客服:1457312923
    Chlorantholide E; Chlorantholide E CFN97969 1372558-36-5 C15H18O5 = 278.3 5mg QQ客服:2159513211
    4alpha,6alpha-Dihydroxyeudesm-11(13)-en-12,8beta-olide; 4alpha,6alpha-Dihydroxyeudesm-11(13)-en-12,8beta-olide CFN89139 35001-19-5 C15H22O4 = 266.33 5mg QQ客服:2159513211
    Wedelialactone A; Wedelialactone A CFN96439 175862-40-5 C24H34O8 = 450.53 5mg QQ客服:1413575084
    6-O-Methacryloyltrilobolide; 6-O-Methacryloyltrilobolide CFN89319 950685-51-5 C23H30O9 = 450.48 5mg QQ客服:2159513211
    Wedeliatrilolactone A; Wedeliatrilolactone A CFN96438 156993-29-2 C23H32O9 = 452.49 5mg QQ客服:1457312923
    4,8-二羟基桉叶-7(11)-烯-12,8-内酯; 4,8-Dihydroxyeudesm-7(11)-en-12,8-olide CFN99348 1231208-53-9 C15H22O4 = 266.3 5mg QQ客服:1413575084
    白术内酯I; 苍术内酯I; Atractylenolide I CFN99944 73069-13-3 C15H18O2 = 230.30 20mg QQ客服:2159513211
    白术内酯II; 苍术内酯II; Atractylenolide II CFN99945 73069-14-4 C15H20O2 = 232.32 20mg QQ客服:3257982914

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产